---
document_datetime: 2025-12-29 08:18:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zoledronic-acid-actavis.html
document_name: zoledronic-acid-actavis.html
version: success
processing_time: 0.3288003
conversion_datetime: 2025-12-30 22:49:30.558756
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zoledronic acid Actavis

[RSS](/en/individual-human-medicine.xml/66248)

##### Authorised

This medicine is authorised for use in the European Union

zoledronic acid Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Zoledronic acid Actavis. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Actavis.

Expand section

Collapse section

## What is Zoledronic acid Actavis?

Zoledronic acid Actavis is a medicine that contains the active substance zoledronic acid (4 mg). It is available as a concentrate to be made into a solution for infusion (drip) into a vein.

Zoledronic acid Actavis is a 'generic medicine'. This means that Zoledronic acid Actavis is similar to a 'reference medicine' already authorised in the European Union (EU) called Zometa.

## What is Zoledronic acid Actavis used for?

Zoledronic acid Actavis can be used to prevent bone complications in adults with advanced cancer that is affecting the bone. This includes fractures (breaks in the bone), spinal compression (when the spinal cord is compressed by the bone), bone disorders needing radiotherapy (treatment with radiation) or surgery, and hypercalcaemia (high levels of calcium in the blood). Zoledronic acid Actavis can also be used to treat the hypercalcaemia caused by tumours.

The medicine can only be obtained with a prescription.

## How is Zoledronic acid Actavis used?

Zoledronic acid Actavis must only be used by a doctor who has experience in the use of this type of medicine given into a vein.

The usual dose of Zoledronic acid Actavis is one infusion of 4 mg over at least 15 minutes. When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderate problems with their kidneys. It is not recommended for patients with severe kidney problems.

## How does Zoledronic acid Actavis work?

The active substance in Zoledronic acid Actavis, zoledronic acid, is a bisphosphonate. It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss. The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.

Patients with tumours can have high levels of calcium in their blood, released from the bones. By preventing the breakdown of bones, Zoledronic acid Actavis also helps to reduce the amount of calcium released into the blood.

## How has Zoledronic acid Actavis been studied?

The company provided data from the published literature on zoledronic acid. No additional studies were needed as Zoledronic acid Actavis is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Zometa.

## What are the benefits and risks of Zoledronic acid Actavis?

Because Zoledronic acid Actavis is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Zoledronic acid Actavis been approved?

The CHMP concluded that, in accordance with EU requirements, Zoledronic acid Actavis has been shown to be comparable to Zometa. Therefore, the CHMP's view was that, as for Zometa, the benefit outweighs the identified risk. The Committee recommended that Zoledronic acid Actavis be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Zoledronic acid Actavis?

A risk management plan has been developed to ensure that Zoledronic acid Actavis is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zoledronic acid Actavis, including the appropriate precautions to be followed by healthcare professionals and patients.

In addition, the company that markets Zoledronic acid Actavis will provide a card to inform patients about the risk of osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth) and to instruct them to contact their doctor if they experience symptoms.

## Other information about Zoledronic acid Actavis

The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic acid Actavis on 20 April 2012.

For more information about treatment with Zoledronic acid Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Zoledronic Acid Actavis : EPAR - Summary for the public

English (EN) (76.39 KB - PDF)

**First published:** 07/05/2012

**Last updated:** 16/06/2016

[View](/en/documents/overview/zoledronic-acid-actavis-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-419)

български (BG) (105.46 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/bg/documents/overview/zoledronic-acid-actavis-epar-summary-public_bg.pdf)

español (ES) (76.55 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/es/documents/overview/zoledronic-acid-actavis-epar-summary-public_es.pdf)

čeština (CS) (100.95 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/cs/documents/overview/zoledronic-acid-actavis-epar-summary-public_cs.pdf)

dansk (DA) (76.04 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/da/documents/overview/zoledronic-acid-actavis-epar-summary-public_da.pdf)

Deutsch (DE) (77.82 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/de/documents/overview/zoledronic-acid-actavis-epar-summary-public_de.pdf)

eesti keel (ET) (75.13 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/et/documents/overview/zoledronic-acid-actavis-epar-summary-public_et.pdf)

ελληνικά (EL) (106.13 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/el/documents/overview/zoledronic-acid-actavis-epar-summary-public_el.pdf)

français (FR) (77.56 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/fr/documents/overview/zoledronic-acid-actavis-epar-summary-public_fr.pdf)

hrvatski (HR) (95.6 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/hr/documents/overview/zoledronic-acid-actavis-epar-summary-public_hr.pdf)

italiano (IT) (75.95 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/it/documents/overview/zoledronic-acid-actavis-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.35 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/lv/documents/overview/zoledronic-acid-actavis-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.76 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/lt/documents/overview/zoledronic-acid-actavis-epar-summary-public_lt.pdf)

magyar (HU) (95.79 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/hu/documents/overview/zoledronic-acid-actavis-epar-summary-public_hu.pdf)

Malti (MT) (101.92 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/mt/documents/overview/zoledronic-acid-actavis-epar-summary-public_mt.pdf)

Nederlands (NL) (76.49 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/nl/documents/overview/zoledronic-acid-actavis-epar-summary-public_nl.pdf)

polski (PL) (102.07 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/pl/documents/overview/zoledronic-acid-actavis-epar-summary-public_pl.pdf)

português (PT) (76.49 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/pt/documents/overview/zoledronic-acid-actavis-epar-summary-public_pt.pdf)

română (RO) (97.57 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/ro/documents/overview/zoledronic-acid-actavis-epar-summary-public_ro.pdf)

slovenčina (SK) (100.15 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/sk/documents/overview/zoledronic-acid-actavis-epar-summary-public_sk.pdf)

slovenščina (SL) (94.03 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/sl/documents/overview/zoledronic-acid-actavis-epar-summary-public_sl.pdf)

Suomi (FI) (75.33 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/fi/documents/overview/zoledronic-acid-actavis-epar-summary-public_fi.pdf)

svenska (SV) (76.12 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

16/06/2016

[View](/sv/documents/overview/zoledronic-acid-actavis-epar-summary-public_sv.pdf)

## Product information

Zoledronic acid Actavis : EPAR - Product Information

English (EN) (467.78 KB - PDF)

**First published:** 07/05/2012

**Last updated:** 01/06/2023

[View](/en/documents/product-information/zoledronic-acid-actavis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-740)

български (BG) (549.95 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/bg/documents/product-information/zoledronic-acid-actavis-epar-product-information_bg.pdf)

español (ES) (475.38 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/es/documents/product-information/zoledronic-acid-actavis-epar-product-information_es.pdf)

čeština (CS) (608.14 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/cs/documents/product-information/zoledronic-acid-actavis-epar-product-information_cs.pdf)

dansk (DA) (495.61 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/da/documents/product-information/zoledronic-acid-actavis-epar-product-information_da.pdf)

Deutsch (DE) (568.57 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/de/documents/product-information/zoledronic-acid-actavis-epar-product-information_de.pdf)

eesti keel (ET) (487.23 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/et/documents/product-information/zoledronic-acid-actavis-epar-product-information_et.pdf)

ελληνικά (EL) (591.89 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/el/documents/product-information/zoledronic-acid-actavis-epar-product-information_el.pdf)

français (FR) (522.29 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/fr/documents/product-information/zoledronic-acid-actavis-epar-product-information_fr.pdf)

hrvatski (HR) (576.69 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/hr/documents/product-information/zoledronic-acid-actavis-epar-product-information_hr.pdf)

íslenska (IS) (507.29 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/is/documents/product-information/zoledronic-acid-actavis-epar-product-information_is.pdf)

italiano (IT) (488.64 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/it/documents/product-information/zoledronic-acid-actavis-epar-product-information_it.pdf)

latviešu valoda (LV) (566.1 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/lv/documents/product-information/zoledronic-acid-actavis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (582.09 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/lt/documents/product-information/zoledronic-acid-actavis-epar-product-information_lt.pdf)

magyar (HU) (638.07 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/hu/documents/product-information/zoledronic-acid-actavis-epar-product-information_hu.pdf)

Malti (MT) (614.47 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/mt/documents/product-information/zoledronic-acid-actavis-epar-product-information_mt.pdf)

Nederlands (NL) (505.85 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/nl/documents/product-information/zoledronic-acid-actavis-epar-product-information_nl.pdf)

norsk (NO) (494.3 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/no/documents/product-information/zoledronic-acid-actavis-epar-product-information_no.pdf)

polski (PL) (566.95 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/pl/documents/product-information/zoledronic-acid-actavis-epar-product-information_pl.pdf)

português (PT) (495.04 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/pt/documents/product-information/zoledronic-acid-actavis-epar-product-information_pt.pdf)

română (RO) (630.67 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/ro/documents/product-information/zoledronic-acid-actavis-epar-product-information_ro.pdf)

slovenčina (SK) (555.54 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/sk/documents/product-information/zoledronic-acid-actavis-epar-product-information_sk.pdf)

slovenščina (SL) (521.71 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/sl/documents/product-information/zoledronic-acid-actavis-epar-product-information_sl.pdf)

Suomi (FI) (506.73 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/fi/documents/product-information/zoledronic-acid-actavis-epar-product-information_fi.pdf)

svenska (SV) (490.21 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

01/06/2023

[View](/sv/documents/product-information/zoledronic-acid-actavis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IG1612 31/05/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zoledronic acid Actavis : EPAR - All Authorised presentations

English (EN) (23.82 KB - PDF)

**First published:** 07/05/2012

**Last updated:** 07/05/2012

[View](/en/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-910)

български (BG) (51.81 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/bg/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.29 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/es/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (45.04 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/cs/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.24 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/da/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.4 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/de/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.63 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/et/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (47.84 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/el/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_el.pdf)

français (FR) (17.25 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/fr/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (17.35 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/it/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (43.43 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/lv/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (43.55 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/lt/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (42.72 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/hu/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (43.97 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/mt/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.34 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/nl/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_nl.pdf)

polski (PL) (44.51 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/pl/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.54 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/pt/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_pt.pdf)

română (RO) (42.8 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/ro/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (43.41 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/sk/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (30.11 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/sl/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.18 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/fi/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.76 KB - PDF)

**First published:**

07/05/2012

**Last updated:**

07/05/2012

[View](/sv/documents/all-authorised-presentations/zoledronic-acid-actavis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zoledronic acid Actavis Active substance zoledronic acid monohydrate International non-proprietary name (INN) or common name zoledronic acid Therapeutic area (MeSH) Fractures, Bone Anatomical therapeutic chemical (ATC) code M05BA08

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.

Treatment of adult patients with tumour-induced hypercalcaemia.

## Authorisation details

EMA product number EMEA/H/C/002488

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Actavis Group PTC ehf

Dalshraun 1

Opinion adopted 16/02/2012 Marketing authorisation issued 20/04/2012 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zoledronic acid Actavis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (537.09 KB - PDF)

**First published:** 25/06/2013

**Last updated:** 01/06/2023

[View](/en/documents/procedural-steps-after/zoledronic-acid-actavis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Zoledronic acid Actavis : EPAR - Public assessment report

Adopted

Reference Number: EMA/225612/2012

English (EN) (243.22 KB - PDF)

**First published:** 07/05/2012

**Last updated:** 07/05/2012

[View](/en/documents/assessment-report/zoledronic-acid-actavis-epar-public-assessment-report_en.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 01/06/2023

## Share this page

[Back to top](#main-content)